Novel Targeted Therapies for Prostate Cancer

Urologic Clinics of North America

Volumn 37, Issue 1, 2010, Pages 105-119

  Macfarlane, Robyn J ^a   Chi, Kim N ^a,b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Androgen receptor; Apoptosis; Bone targeted therapy; Chaperone proteins; Growth factor receptor; Prostate cancer

Indexed keywords

ABIRATERONE ACETATE; AFLIBERCEPT; ANTINEOPLASTIC AGENT; ATRASENTAN; BEVACIZUMAB; BICALUTAMIDE; CEDIRANIB; CP 751871; DASATINIB; DEFOROLIMUS; DENOSUMAB; DOCETAXEL; ESTRAMUSTINE; EVEROLIMUS; HORMONE RECEPTOR BLOCKING AGENT; ISOSORBIDE; MDV 3100; MITOXANTRONE; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; OBLIMERSEN; OGX 011; PLACEBO; PREDNISONE; RAPAMYCIN; SATRAPLATIN; SORAFENIB; SUNITINIB; TANESPIMYCIN; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANOREXIA; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; BLEEDING; BONE METASTASIS; BONE NECROSIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; HEART FAILURE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEINURIA; RECOMMENDED DRUG DOSE; REVIEW; RHINITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SMALL INTESTINE OBSTRUCTION; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; VASODILATATION;

ANTINEOPLASTIC AGENTS; HUMANS; MALE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 75249099988     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2009.11.011     Document Type: Review

References (124)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 58 (2008) 71-96
2. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
3. Scher H.I., Halabi S., Tannock I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 26 (2008) 1148-1159
4. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
5. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14 (1996) 1756-1764
6. Oosterhof G.O., Roberts J.T., de Reijke T.M., et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 44 (2003) 519-526
7. Saad F., Gleason D.M., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 (2002) 1458-1468
8. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
9. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
10. Debes J.D., and Tindall D.J. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351 (2004) 1488-1490
11. Feldman B.J. The development of androgen-independent prostate cancer. Nat Rev Cancer 1 (2001) 34-35
12. Fossa S.D., Slee P.H., Brausi M., et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the european organization for research and treatment of cancer genitourinary group. J Clin Oncol 19 (2001) 62-71
13. Linja M.J., Savinainen K.J., Saramaki O.R., et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61 (2001) 3550-3555
14. Chen C.D., Welsbie D.S., Tran C., et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10 (2004) 33-39
15. Mohler J.L., Gregory C.W., Ford III O.H., et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 10 (2004) 440-448
16. Snoek R., Cheng H., Margiotti K., et al. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res 15 (2009) 39-47
17. Titus M.A., Schell M.J., Lih F.B., et al. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11 (2005) 4653-4657
18. Stanbrough M., Bubley G.J., Ross K., et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66 (2006) 2815-2825
19. Holzbeierlein J., Lal P., LaTulippe E., et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164 (2004) 217-227
20. Locke J.A., Guns E.S., Lubik A.A., et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68 (2008) 6407-6415
21. Hu R., Dunn T.A., Wei S., et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69 (2009) 16-22
22. Attar R.M., Jeur-Kunkel M., Balog A., et al. Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer. Cancer Res 69 16 (2009) 6522-6530
23. Attard G., Reid A.H., Yap T.A., et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26 (2008) 4563-4571
24. Ryan C., Efstathios E., Smith M., et al. Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone [abstract]. J Clin Oncol 27 (2009) 5046
25. Reid A.H., Attard G., Danila D., et al. A multicenter phase II study of abiraterone acetate (AA) in docetacel pretreated castration-resistant prostate cancer (CRPC) patients (pts) [abstract]. J Clin Oncol 27 (2009) 5047
26. Danila D.C., de Bono J., Ryan C.J., et al. Phase II multicenter study of abiraterone acetate (AA) plus prednisone therapy in docetaxel-treated castration-resistant prostate cancer (CRPC) patients (pts): impact of prior ketoconazole (keto) [abstract]. J Clin Oncol 27 (2009) 5048
27. Scher H.I., Beer T.M., Higano C.S., et al. Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC) [abstract]. J Clin Oncol 27 (2009) 5011
28. Huss W.J., Hanrahan C.F., Barrios R.J., et al. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 61 (2001) 2736-2743
29. George D.J., Halabi S., Shepard T.F., et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on cancer and leukemia group B 9480. Clin Cancer Res 7 (2001) 1932-1936
30. Melnyk O., Zimmerman M., Kim K.J., et al. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol 161 (1999) 960-963
31. Jain R.K., Tong R.T., and Munn L.L. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 67 (2007) 2729-2735
32. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 5 (2003) 427-434
33. Picus J., Halabi S., Rini B., et al. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): Initial results of CALGB 90006 [abstract]. Proc Am Soc Clin Oncol 22 (2003) 1578
34. Gross M.E., Soscia J., Sakowsky S., et al. Phase I trial of RAD001, bevacizumab, and docetaxel for castration-resistant prostate cancer (CRPC) [abstract]. J Clin Oncol 27 (2009) 5154
35. Vaishampayan U.N., Heilbrun L.K., Heath E.I., et al. Phase II trial of bevacizumab and oral satraplatin and prednisone in docetaxel pretreated metastatic castrate resistant prostate cancer [abstract]. J Clin Oncol 27 (2009) e16028
36. Verheul H.M., Hammers H., van Erp K., et al. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 13 (2007) 4201-4208
37. Isambert N., Freyer G., Zanetta S., et al. A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: preliminary results [abstract]. J Clin Oncol 26 (2008) 3599
38. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
39. Periman P.O., Sonpavde G., Bernold D.M., et al. Sunitinib malate for metastatic castration resistant prostate cancer following docetaxel-based chemotherapy [abstract]. J Clin Oncol 26 (2008) 5157
40. Zurita A.J., Liu G., Hutson T., et al. Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer [abstract]. J Clin Oncol 27 (2009) 5166
41. Escudier B., Eisen T., Stadler W.M., et al. TARGET Study Group Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 2 (2007) 125-134
42. Llovet J.M., Ricci S., Mazzaferro V., et al. SHARP Investigators Study Group Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 4 (2008) 378-390
43. Chi K.N., Ellard S.L., Hotte S.J., et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 19 4 (2008) 746-751
44. Aragon-Ching J.B., Jain L., Gulley J.L., et al. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 103 12 (2009) 1636-1640
45. Mardjuadi F., Medioni J., Kerger J., et al. A phase I study of sorafenib in association with docetaxel-prednisone in chemonaive metastatic castration-resistant prostate cancer [abstract]. J Clin Oncol 27 (2009) 5153
46. Cetnar J.P., Rosen M.A., Vaughn D.J., et al. Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer [abstract]. J Clin Oncol 27 (2009) e16055
47. Nabhan C., Tolzein K., Lestingi T.M., et al. Effect of sorafenib on chemotherapy resistance and refractoriness in castration-resistant prostate cancer [abstract]. J Clin Oncol 27 (2009) e16105
48. Karakunnel J.J., Gulley J.L., Arlen P., et al. Cediranib (AZD2171) in docetaxel-resistant, castration-resistant prostate cancer [abstract]. J Clin Oncol 27 (2009) 5141
49. Krajewska M., Krajewski S., Epstein J.I., et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148 (1996) 1567-1576
50. Raffo A.J., Perlman H., Chen M.W., et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55 (1995) 4438-4445
51. Miyake H., Nelson C., Rennie P.S., et al. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 60 (2006) 170-176
52. Chi K.N., Gleave M.E., Klasa R., et al. A phase I dose-finding study of combined treatment with an antisense bcl-2 oligonucleotide (genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 7 (2001) 3920-3927
53. Tolcher A.W., Chi K., Kuhn J., et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 11 (2005) 3854-3861
54. Sternberg CN, Dumez H, Van Poppel H, et al. Multicenter randomized EORTC trial 30021 of docetaxel + oblimersen and docetaxel in patients (pts) with hormone refractory prostate cancer (HRPC) [abstract]. The Prostate Cancer Symposium (ASCO, ASTRO, SUO); 2007:144.
55. Yamanaka K., Rocchi P., Miyake H., et al. A novel antisense oligonucleotide inhibiting several antiapoptotic bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther 4 (2005) 1689-1698
56. Liu G, Wilding G, Somer B, et al. An open-label, multicenter, phase II study of single-agent AT-101 in men with hormone refractory prostate cancer (HRPC) and rising prostate-specific antigen (PSA) levels who have not received prior chemotherapy [abstract]. Prostate Cancer Symposium (ASCO, ASTRO, SUO); 2007:258.
57. MacVicar G.R., Greco A., Reeves J., et al. An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel and prednisone in men with castrate-resistant prostate caner [abstract]. J Clin Oncol 27 (2009) 5062
58. Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 15 (2009) 9-14
59. Edwards A., Li J., Atadja P., et al. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther 6 (2007) 2515-2524
60. Pratt W.B., Galigniana M.D., Morishima Y., et al. Role of molecular chaperones in steroid receptor action. Essays Biochem 40 (2004) 41-58
61. Marrocco D.L., Tilley W.D., Bianco-Miotto T., et al. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther 6 (2007) 51-60
62. Welsbie D.S., Xu J., Chen Y., et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 69 (2009) 958-966
63. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648
64. Iljin K., Wolf M., Edgren H., et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 66 (2006) 10242-10246
65. Bjorkman M., Iljin K., Halonen P., et al. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. Int J Cancer 123 (2008) 2774-2781
66. Heath E.I., Hillman D.W., Vaishampayan U., et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 14 (2008) 7940-7946
67. Hussain M., Dunn R., Rathkopf D., et al. Suberoylanilide hydroxamic acid (vorinostat) post chemotherapy in hormone refractory prostate cancer (HRPC) patients (pts): a phase II trial by the prostate cancer clinical trials consortium (NCI 6862). J Clin Oncol 25 (2007) 5132
68. Leskov K.S., Klokov D.Y., Li J., et al. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 278 (2003) 11590-11600
69. Zhang H., Kim J.K., Edwards C.A., et al. Clusterin inhibits apoptosis by interacting with activated bax. Nat Cell Biol 7 (2005) 909-915
70. Humphreys D.T., Carver J.A., Easterbrook-Smith S.B., et al. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem 274 (1999) 6875-6881
71. Ammar H., and Closset J.L. Clusterin activates survival through the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 283 (2008) 12851-12861
72. Gleave M., and Chi K.N. Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers. Ann N Y Acad Sci 1058 (2005) 1-15
73. July L.V., Akbari M., Zellweger T., et al. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50 (2002) 179-188
74. Chi K.N., Eisenhauer E., Fazli L., et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97 (2005) 1287-1296
75. Chi K.N., Siu L.L., Hirte H., et al. A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 14 (2008) 833-839
76. Saad F., Hotte S.J., North S.A., et al. A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1st-line docetaxel therapy [abstract]. J Clin Oncol 26 (2008) 5002
77. Chi K.N., Hotte S.J., Yu E., et al. A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC) [abstract]. J Clin Oncol 25 (2007) 5069
78. Chi K.N., Hotte S.J., Yu E., et al. Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer [abstract]. J Clin Oncol 27 (2009) 5012
79. Renehan A.G., Zwahlen M., Minder C., et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363 (2004) 1346-1353
80. Chan J.M., Stampfer M.J., Ma J., et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94 (2008) 1099-1106
81. Hellawell G.O., Turner G.D., Davies D.R., et al. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 62 (2002) 2942-2950
82. Krueckl S.L., Sikes R.A., Edlund N.M., et al. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 64 (2004) 8620-8629
83. Wu J.D., Odman A., Higgins L.M., et al. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 11 (2005) 3065-3074
84. Higano C., Alumkal J., Ryan C.J., et al. A phase II study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody, against the insulin-like growth factor-1 receptor, as monotherapy in patients with metastatic, asymptomatic castration-resistant prostate cancer [abstract]. J Clin Oncol 27 (2009) 5142
85. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2 (2002) 489-501
86. Gera J.F., Mellinghoff I.K., Shi Y., et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol 279 (2004) 2737-2746
87. Mousses S., Wagner U., Chen Y., et al. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 20 41 (2007) 6718-6723
88. Wang Y., Mikhailova M., Bose S., et al. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene 27 56 (2008) 7106-7117
89. Yoshimoto M., Joshua A.M., Cunha I.W., et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 21 12 (2008) 1451-1460
90. Amato R.J., Jac J., Mohammad T., et al. Pilot study of rapamycin in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer 6 2 (2008) 97-102
91. Wan X., Harkavy B., Shen N., et al. Rapamycin induces feedback activation of akt signaling through an IGF-1R-dependent mechanism. Oncogene 26 (2007) 1932-1940
92. Hofbauer L.C., and Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292 (2004) 490-495
93. Chen G., Sircar K., Aprikian A., et al. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107 (2006) 289-298
94. Brown J.M., Vessella R.L., Kostenuik P.J., et al. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 7 (2001) 2977-2983
95. Ellis G.K., Bone H.G., Chlebowski R., et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26 (2008) 4875-4882
96. Bone H.G., Bolognese M.A., Yuen C.K., et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93 (2008) 2149-2157
97. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23 (2005) 8580-8587
98. Nelson J.B., Hedican S.P., George D.J., et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1 (1995) 944-949
99. Carducci M.A., and Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 12 (2006) 6296-6300
100. Carducci M.A., Saad F., Abrahamsson P.A., et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110 (2007) 1959-1966
101. Nelson J.B., Love W., Chin J.L., et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 113 (2008) 2478-2487
102. Armstrong A.J., Creel P., Turnbull J., et al. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 14 (2008) 6270-6276
103. James N.D., Caty A., Borre M., et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 55 5 (2008) 1112-1123
104. Tatarov O., Mitchell T.J., Seywright M., et al. Src family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res 15 10 (2009) 3540-3549
105. Fizazi K. The role of src in prostate cancer. Ann Oncol 18 (2007) 1765-1773
106. Nam S., Kim D., Cheng J.Q., et al. Action of the src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 65 (2005) 9185-9189
107. Yu E.Y., Wilding G., Posadas E., et al. Dasatinib in patients with hormone-refractory progressive prostate cancer: a phase II study [abstract]. J Clin Oncol 26 (2008) 5156
108. Yu E., Massard C., Gross M., et al. A phase II study of once-daily dasatinib for patients with castration-resistant prostate cancer [abstract]. J Clin Oncol 27 (2009) 5147
109. Araujo J., Armstrong A.J., Braud E.L., et al. Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: a phase I/II study [abstract]. J Clin Oncol 27 (2009) 5061
110. Serafini A.N., Houston S.J., Resche I., et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 16 4 (1998) 1574-1581
111. Sartor O., Reid R.H., Hoskin P.J., et al. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 63 5 (2004) 940-945
112. 153Sm-EDTMP in patients with castration-resistant prostate cancer [abstract]. J Clin Oncol 27 (2009) 5155
113. Morris M.J., Pandit-Taskar N., Stephenson R.D., et al. Phase I/II study of docetaxel and 153-sm for castrate metastatic prostate cancer: summary of dose-escalation cohorts and first report of the expansion cohort [abstract]. J Clin Oncol 27 (2009) 5057
114. Fizazi K., Beuzeboc P., Lumbroso J., et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 27 (2009) 2429-2435
115. Bellmunt J., Rosenberg J.E., and Choueiri T.K. Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer. Eur Urol 56 4 (2009) 606-608
116. Nilsson S., Franz L., Parker C., et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre placebo-controlled phase II study. Lancet Oncol 8 7 (2007) 587-594
117. Altmann K.H. Recent developments in the chemical biology of epothilones. Curr Pharm Des 11 13 (2005) 1595-1613
118. Julien B., and Shah S. Heterologous expression of epothilone biosynthetic genes in Myxococcus xanthus. Antimicrobial Agents Chemother 46 9 (2002) 2772-2778
119. Rosenberg J.E., Weinberg V.K., Kelly W.K., et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 110 3 (2007) 556-563
120. Wilding G., Chen Y., DiPaola R.P., et al. Updated results on phase II study of a weekly schedule of BMS-247550 for patients with castrate refractory prostate cancer [abstract]. J Clin Oncol 26 (2008) 5070
121. Small E., Harzstark A., Weinberg V.K., et al. Ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer refractory to docetaxel-based therapy: a phase II study of the DOD prostate cancer clinical trials consortium [abstract]. J Clin Oncol 27 (2009) 5058
122. Hussain A., Dipaola R.S., Baron A.D., et al. A phase IIa trial of weekly EPO906 in patients with hormone-refractory prostate cancer [abstract]. J Clin Oncol 22 (2004) 4563
123. Beardsley E.K., Saad F., Eigl B., et al. A phase II study of patupilone in patients with metastatic castration-resistant prostate cancer who have progressed after docetaxel [abstract]. J Clin Oncol 27 (2009) 5139
124. Beer T.M., Smith D.C., Hussain A., et al. Phase II study of first-line sagopilone combined with prednisone in patients with metastatic castration-resistant prostate cancer [abstract]. J Clin Oncol 27 (2009) 5059